Clinical trial · Observational
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Effects of Neoadjuvant Immunotherapy on Patients With Lung Cancer: a Prospective, Observational Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Immunotherapy | — | UNRESOLVED | — |
| Lung Cancer, Non-Small Cell | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-Tumor Drugs | Drug | — | UNRESOLVED |
| lobectomy | Procedure | — | UNRESOLVED |
| Pneumonectomy | Procedure | — | UNRESOLVED |
| radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Surgery
- description
- Patients will undergo surgery after neoadjuvant immunotherapy.
- interventionNames
- Procedure: Pneumonectomy
- Procedure: lobectomy
- label
- Non-surgery
- description
- Patients will receive non-surgical treatment after neoadjuvant treatment.
- interventionNames
- Radiation: radiotherapy
- Drug: Anti-Tumor Drugs
Primary outcomes (1)
- measure
- Event-free survival
- timeFrame
- Event-free survival was defined as the time from neoadjuvant treatment to metastasis or death by any cause in the absence of metastasis, up to approximately 10 years.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged between 18 and 79 years; 2. Received at least two cycles of neoadjuvant immunotherapy; 3. ECOG performance status score of 0; 4. Complete clinical information including imaging data available. Exclusion Criteria: 1. Diagnosed with or suspected active autoimmune diseases; 2. Presence of EGFR/ALK sensitive mutations; 3. Pregnant or breastfeeding women; 4. Previous anti-tumor therapies including chemotherapy or radiotherapy; 5. History of organ transplantation or hematopoietic stem cell transplantation; 6. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema; 7. Uncontrolled diabetes mellitus; 8. Uncontrolled hypertension.
References
Publications (0)
Data not yet available